Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat

Stopped Feasibility cohorts competed. Efficacy cohort not initiated for business reasons

Conditions

• Excess Submental Fat ("Double Chin")

Interventions

• DRUG: XAF5 Gel
• DRUG: Placebo Gel

Sponsor

Topokine Therapeutics, Inc.